Quanterix to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Quanterix (NASDAQ: QTRX), a leader in ultrasensitive biomarker detection, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Masoud Toloue, will deliver a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PST at the Westin St. Francis Hotel in San Francisco.

The presentation will be accessible via live webcast through the Investors section of Quanterix's website. The company will also conduct one-on-one meetings with institutional investors during the conference. A replay of the webcast will be available for a time after the event.

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the 43^rd Annual J.P. Morgan Healthcare Conference taking place January 13^th-16^th at the Westin St. Francis Hotel in San Francisco, CA. Quanterix’s presentation will be on Wednesday, January 15, 2025, at 4:30 p.m., PST. In addition to the session, Quanterix will also host one-on-one meetings with institutional investors during the conference.

Webcast Information

The live webcast presentation can be accessed from the Investors section of the company’s website at www.quanterix.com. A replay of the webcast will be available for a limited period following the conference.

To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix’s Simoa® technology, visit www.quanterix.com/simoa-technology.

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,100 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250102680151/en/

Media Contact:

Marissa Klaassen

media@quanterix.com

Investor Relations Contact:

Joshua Young

ir@quanterix.com

Source: Quanterix Corporation

FAQ

When is Quanterix (QTRX) presenting at the 2025 J.P. Morgan Healthcare Conference?

Quanterix (QTRX) is scheduled to present on Wednesday, January 15, 2025, at 4:30 p.m. PST at the Westin St. Francis Hotel in San Francisco.

How can investors access Quanterix's (QTRX) J.P. Morgan Healthcare Conference presentation?

Investors can access the live webcast through the Investors section of Quanterix's website at www.quanterix.com. A replay will be available for a time after the conference.

Will Quanterix (QTRX) be conducting investor meetings at the J.P. Morgan Healthcare Conference?

Yes, Quanterix will be hosting one-on-one meetings with institutional investors during the conference.

What is the duration of the 2025 J.P. Morgan Healthcare Conference where QTRX is presenting?

The 43rd Annual J.P. Morgan Healthcare Conference runs from January 13th through January 16th, 2025.